Pancreatic proglucagon gene expression is promoted upon fasting and hypoglycaemia induction and inhibited by insulin
JAMA 311 , 18891900 (2014)
Statements Author contributions CG, SiS, TA, and TK wrote the manuscript, reviewed the literature, and collected the information
It is typically an intramuscular injection in the arm, and is given by a nurse or a doctor
The findings indicate that: 67% of Omada members were persistent on their medication at one year and experienced weight loss comparable to clinical trials Average weight loss at one year in the program was 18.4% for members persistent on medication and 13.1% for members who discontinued before one year In terms of engagement, members completed more than 10 actions a week on average This data suggests that providing the right kind of support to promote GLP-1 persistence can help patients achieve clinical trial-level weight loss, setting the stage for cardiometabolic disease risk reduction
Resveratrol role in autoimmune disease-a mini-review